**APPENDIX A: DATABASE SEARCHES**

PUBMED Search Strategy

|  |  |  |
| --- | --- | --- |
| SEARCH | QUERY | ITEMS FOUND |
| #2 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV RTPA | 1 |
| #1 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV THROMBOLYSIS | 2 |
| #3 | DIABETES MELLITUS AND PREVIOUS STROKE AND IV THROMBOLYSIS | 11 |
| #4 | DIABETES MELLITUS AND PREVIOUS STROKE AND IV RTPA | 2 |

ClinicalTrials.gov Search Strategy

|  |  |  |
| --- | --- | --- |
| SEARCH | QUERY | ITEMS FOUND |
| #1 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV RTPA | 0 |
| #2 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV THROMBOLYSIS | 0 |

Cochrane Central Register of Controlled Trials

|  |  |  |
| --- | --- | --- |
| SEARCH | QUERY | ITEMS FOUND |
| #1 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV THROMBOLYSIS | 1 |
| #2 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV RTPA | 0 |

Scopus

|  |  |  |
| --- | --- | --- |
| SEARCH | QUERY | ITEMS FOUND |
| #1 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV THROMBOLYSIS | 1 |
| #2 | DIABETES MELLITUS AND PREVIOUS CEREBRAL INFARCTION AND IV RTPA | 0 |

**APPENDIX B: CHARACTERISTICS OF INCLUDED STUDIES**

|  |  |  |  |
| --- | --- | --- | --- |
| Studies Included | Population | Intervention | Outcomes Measured |
| Authors/Year published/Design | Country/Sample/Inclusive dates | Inclusion Criteria | Exclusion Criteria | Dose of IV-rtPA |
| Mishra et al., 2011Retrospective Cohort (Registry-Based) | Stockholm, SwedenSafe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register (SITS-ISTR)Virtual International Stroke Trials Archive (VISTA) December 2002-November 2009. | Patients who fulfilled the SITS-MOST criteria for intravenous thrombolysis (IVT) IV-rtPA in a standard 0.9 mg/kg dose within 3 - 4.5-h time window from stroke onset.(+) consent for data to be included in the registry. | Non-ischemic strokeMissing data on Modified Rankin Scale at 90 daysBeyond the time windowIncomplete and erroneous dataStroke within the last three months  | 0.9 mg/kg dose of IV-rtPA  | * Favorable outcome (mRS 0-2)
* Uunfavorable outcome mRS (3-5)
* Death
 |
| Fuentes et al., 2011Observational analysis of a multi-centre stroke registry with prospective inclusion. (Registry-based) | Madrid Stroke Network.January 2003-December 2010. | Patients who fulfilled the SITS-MOST criteria for intravenous thrombolysis (IVT) IV-rtPA in a standard 0.9 mg/kg dose within 3 - 4.5-h time window from stroke onset.(+) consent for data to be included in the registry. | Non-ischemic strokeMissing data on Modified Rankin Scale at 90 daysBeyond the time windowIncomplete and erroneous dataStroke within the last three months | 0.9 mg/kg dose of IV-rtPA  | * Favorable outcome (mRS 0-2)
* Uunfavorable outcome mRS (3-5)
* Death
* sICH
 |
| Filipov et al., 2018Restrospective Review (Stroke Database)  | GermanyJanuary 2013-July 2015 | Patients who underwent IVT after standardized stroke treatment and workup according to national guidelines. | NA | NA | * sICH
* Outcome in terms of mRS
* Death
 |
| Ehrlich, M. et al., 2019Observational (Cohort) analysis of a multicentre stroke registry with prospective inclusion.(Registry-based) | United StatesGet with the Guidelines-Stroke Registry February 2009-September 2017  | Patients from GWTG-Stroke from February 2009 to October 2017 who were treated with IV tPA between 3 and 4.5 hours from symptom onset or last known well time. | In-hospital stroke.Received experimental IV tPA or catheter-based treatments, were treated with IV tPA at another hospital, transferred in from another hospital, or had missing data in medical history. Patients were excluded who had either prior stroke or DM but not both. | 0.9 mg/kg dose of IV-rtPA | * sICH
* Outcome in terms of mRS
* Death
 |

|  |  |  |
| --- | --- | --- |
| **APPENDIX C: Newcastle-Ottawa Scale****Newcastle–Ottawa Scale for Cohort Studies** |  |  |
| **Study, Year(Reference)** | **Selection** |  | **Comparability** |  | **Outcome** | **Aggregate score** |
| **Representativeness of the exposed cohort(maximum:\*)** | **Selection of the non-exposed cohort (maximum:\*)** | **Ascertainment of exposure(maximum:\*)** | **Demonstration that outcome of interest was not present at start of study (maximum:\*)** |  | **Comparability of cohorts on the basis of the design or analysis (maximum:\*\*)** |  | **Assessment of outcome(maximum:\*)** | **Was follow up long enough for outcomes to occur (maximum:\*)** | **Adequacy of follow up of cohorts (maximum:\*)**  |  |
| **Fuentes et al. 2011** | \* | \* | \* | \* |  |  |  |  | \* | \* | \*\*\*\*\*\* |
| **Mishra et al. 2011** | \* | \* | \* | \* |  |  |  |  | \* | \* | \*\*\*\*\*\* |
| **Filipov et al., 2018** | \* | \* | \* | \* |  |  |  |  | \* | \* | \*\*\*\*\*\* |
| **Ehrlich, et al., 2019** | \* | \* | \* | \* |  |  |  |  | \* | \* | \*\*\*\*\*\* |